Vildagliptin, a New Treatment for Type 2 Diabetes (NIDDM) Improves Blood Sugar Control
Vildagliptin, a new treatment for type 2 diabetes is reported to be more effective in blood sugar control. It does not cause weight gain and is associated with a low incidence of hypoglycaemia. Vildagliptin is available both alone and in a combination tablet with metformin and offers physicians prescribing flexibility and convenience for patients. Vildagliptin, an oral treatment for type2 diabetes, demonstrated additional reductions in HbA1c of 1.1% versus placebo when added to metformin(1).
Weight gain is a major side effect the traditional type 2 diabetes brings with them. Vildagliptin in combination with metformin has been shown not to increase mean body weight in clinical trials.
Vildagliptin has been studied extensively in over 10,000 patients worldwide across diverse patient populations. It is expected to be prescribed mainly for dual oral therapy in combination with metformin. This is applied in patients with insufficient glycaemic control despite on maximal tolerated dose of monotherapy with metformin(9). Doctors term it as an effective treatment that offered a potential solution to this very real problem of weight gain.
Dr Marc Evans, Consultant Diabetologist, Llandough Hospital, Cardiff, highlights the importance of this in advance: “Vildagliptin helps the body respond appropriately to blood glucose levels. It offers a promising treatment for the significant proportion of patients whose blood sugar levels are above target levels and are therefore at risk of microvascular and macrovascular complications.”
Source: FOX BUSINESS
Filed under Diabetes, Diabetes Drug
